Validation of carbapenemase and extended-spectrum -lactamase multiplex endpoint PCR assays according to ISO 15189 | Zendy

Pierre Bogaerts | Zendy; Roberta Rezende de Castro | Zendy; Ricardo De Mendonça | Zendy; TeDin Huang | Zendy; Olivier Denis | Zendy; Y. Glupczynski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Validation of carbapenemase and extended-spectrum -lactamase multiplex endpoint PCR assays according to ISO 15189

Author(s) -

Pierre Bogaerts,

Roberta Rezende de Castro,

Ricardo De Mendonça,

TeDin Huang,

Olivier Denis,

Y. Glupczynski

Publication year - 2013

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt065

Subject(s) - multiplex polymerase chain reaction , multiplex , accreditation , amplicon , external quality assessment , broth microdilution , biology , medicine , microbiology and biotechnology , bioinformatics , polymerase chain reaction , gene , antibiotics , minimum inhibitory concentration , genetics , pathology , medical education

To validate and accredit a set of three multiplex endpoint PCR assays, targeting the most important carbapenemase and minor extended-spectrum β-lactamase (ESBL) resistance genes, according to the international ISO 15189 particular requirements for the quality and competence of medical laboratories.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research